Skip to main content

Lewy Body Dementia Treatment Market to Showcase Vigorous Demand during the Period until 2028

The purpose of this comprehensive forecast report presented by Fact.MR is to elaborate the various market projections impacting the global lewy body dementia treatment market size during the period through 2018-2028. This assessment delivers high-end statistics concerning market size, growth in trends and revenue share (US& Mn) linked to different geographies and segmentation types. Readers can acquire precise insights about market growth trends along with upcoming opportunities that are expected to reshape the overall structure of the lewy body dementia treatment market during the forecast period.
Global sales of lewy body dementia treatment were valued at over US$ 3,500 Mn in 2018, in line with wide-spread prevalence of lewy body dementia and subsequent need for effective treatment. Cholinesterase inhibitors, valued at over US$ 2,100 Mn in 2018, will continue to remain the most lucrative category, followed by antipsychotic drugs. The minimal side effects associated with these two drug types are among the key reasons fuelling demand for these products. North America will remain the largest market for lewy body dementia treatment in 2019 and beyond, owing to appropriate dementia drug regulations and superior healthcare infrastructure in the region. East Asia is anticipated to emerge as the fastest-growing market for lewy body dementia treatment, as China and India spearhead demand with an ever-growing geriatric population.
Key Growth Drivers - Lewy Body Dementia Treatment Market 

  • Government initiatives aimed at creating awareness about lewy body dementia treatment are likely to uphold growth of the market. For instance, the US has signed into a law the BOLD Infrastructure for Alzheimer’s Act, an initiative aimed at forming a public health model against Alzheimer’s disease and other dementias. The law would sanction approx. US$ 100 Mn over a period of five years to enhance public education, reinforce numerous dementia initiatives being taken by various health and social service agencies, and collect and distribute data related to cognitive decline. Additionally, the increase in funding for lewy body dementia treatment has been reinforced by the novel R&D initiative by the National Institutes of Health (NIH).
  • Increasing prevalence of lewy body dementia and the absence of concerned drugs to manage this ailment is influencing pharma companies to invest in R&D. Currently, Alzheimer’s treatment drugs are used for managing lewy body dementia; however, it is highly likely that a range of generic drugs will proliferate the market in the near future.
  • The high cost of lewy body dementia treatment has prompted healthcare providers to bring certain aspects under the ambit of reimbursements. Favorable regulations pertaining to lewy body dementia treatment have meant that economically weaker sections of the society have access to quality care, which in turn has opened up opportunities for pharmaceutical companies.
  • The burgeoning number of performed clinical trials for lewy body dementia treatment is underpinning gains in the market by bolstering the efficiency of the existing treatment options. Ongoing treatment trials for better lewy body dementia medication have the potential to drive market growth substantially, provided these trials result in successful outcomes. 
Key Challenges Faced by Stakeholders in Lewy Body Dementia Treatment Market 
The adverse effects of drugs used in lewy body dementia treatment are denting consumer and caregiver confidence, creating significant challenges for market growth. For instance, long term exposure to widely used cholinesterase inhibitors for symptomatic treatment of lewy body dementia can cause side effects, such as vomiting, diarrhea, weight loss, and insomnia. The numerous side effects associated with lewy body dementia treatment drugs have been restricting the growth of lewy body dementia treatment market.
Other players operating in the lewy body dementia treatment market and profiled in the report include BioArctic AB, Sumitomo Dainippon Pharma Co., Ltd., Jazz Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., Eli Lilly and Company, Novartis AG, Pfizer Inc., Bayer AG, Mylan NV, Sanofi AG, Teva Pharmaceuticals, GlaxoSmithKline, Eisai Co., Ltd., Takeda Pharmaceutical Company Ltd., Allergan Plc., Janssen Pharmaceuticals, Inc., Bausch Health Companies Inc., and Mallinckrodt Pharmacauticals.     
Ask Industry Experts about this Report - https://www.factmr.com/connectus/sample?flag=AE&rep_id=1154
The rise in ageing population has been gradually increasing the patient pool for lewy body dementia treatment market, with leading manufacturers working on introducing new products tailored to solely focus on lewy body dementia. Pharma companies are focusing on the development of highly innovative and competitive pipeline products. To capitalize on the changing healthcare patterns, manufacturers are diversifying their treatment offerings and business expansion via strategic tie-ups with primary care hospitals and clinics in the Asian and European countries. 
Labels:

Comments

Post a Comment

Popular posts from this blog

Electrosurgery Devices Market: Radiofrequency Electrosurgery Devices will Remain the Top-Selling Product

On the back of rising ageing population, increased instances of surgical procedures and technological innovations, the market for electrosurgical devices is likely to slate lucrative growth triggers in the coming years. Significant spike in surgical procedures pertaining neurology, cardiology, gynecology, and several other general surgeries, electrosurgery devices market is in the cusp of exponential growth. Owing to technological innovations the electrosurgery market in North America has demonstrated growth traction over the years. However, increased healthcare spending towards minimally invasive treatment in Asia-Pacific region is expected to propel the market forward, thus contributing as one of the fastest regional hub in electrosurgery devices market. However, factors such as significant product recalls owing to incompliance with FDA framework remain potential challenges for the growth trajectory. Get sample of this report at https://www.factmr.com/connectus/sample?flag=S...
Post a Comment
Read more

North America to Maintain its Leader Status for the Dermatology Devices Market

 Increasing geriatric population across the world have propelled the demand for the dermatology devices, which in turn has contributed to the growth of the dermatology devices market. Rising adoption of dermatology devices in parallel to the rapid adoption of technology in the dermatology clinics and hospitals for treating skin disorders have been prominent factors for the growth of dermatology devices market. Spur in the spending capability of consumers have facilitated the access to these devices. Pervasiveness of skin disorders has been rising at the global level, which has created demand for acute treatment devices. Developments in the treatment methodologies such as liposuction devices and laser instruments have been successful in attracting the attention of the consumers. A recent report published by Fact.MR states that the global dermatology devices market is anticipated to surpass the whopping value of US$ 1,000 Mn by 2022. Browse Full Report with TOC 'https://www.factm...
Post a Comment
Read more

Lithotripsy Devices Market: Non-Invasive ESWL Witnessing Immense Traction

The report offers a crisp overview of the lithotripsy devices market, which includes an introduction to the lithotripsy devices market in tandem with a definition of the target product – lithotripsy devices. A systematic breakdown of the lithotripsy devices market has been offered in this chapter, which implies scope of the research involved. Size of lithotripsy devices market has been studied in terms of volume (tons) and value (MN), and forecast on the lithotripsy devices market has been offered for the period between 2018 and 2026. The lithotripsy devices market is projected to continue its steady growth due to the burgeoning cases of kidney stones, coupled with the surging demand for minimally invasive medical treatments. According to Fact.MR report, the  lithotripsy devices market  is anticipated to accelerate at 4.3% CAGR during 2018-2026 to reach a value of US$ 1,095.2 MN by the end of 2026. In recent past, lithotripsy has become the most pref...
Post a Comment
Read more